

§ 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

### *Amendments*

#### *In the Claims:*

Please cancel claims 2-5, 9, 11-14, 18, 23, 24, 27 and 29-35 without prejudice or disclaimer.

Please substitute the following claim 1 for pending claim 1:

1. (twice amended) A pharmaceutical composition comprising an inhibitor of human osteonectin and a pharmaceutically acceptable carrier, wherein said inhibitor has an activity selected from the group consisting of: preventing expression of human osteonectin in tumour cells and decreasing expression of human osteonectin in tumour cells, and wherein said inhibitor comprises an antisense polynucleotide which binds to osteonectin mRNA so as to prevent or decrease expression of human osteonectin by preventing or decreasing translation of said mRNA into human osteonectin.

Please substitute the following claim 6 for pending claim 6:

6. (twice amended) The composition according to Claim 1, wherein said antisense polynucleotide is an antisense RNA complimentary to human osteonectin mRNA.

Please substitute the following claim 7 for pending claim 7:

7. (twice amended) The composition according to Claim 1, wherein said inhibitor is conjugated to or administered in combination with a carrier molecule.

Please substitute the following claim 10 for pending claim 10:

10. (twice amended) A method of tumour therapy comprising administering to a patient in need thereof an effective amount of an inhibitor of human osteonectin, wherein said inhibitor has an activity selected from the group consisting of: preventing expression of human osteonectin in tumour cells and decreasing expression of human osteonectin in tumour cells, and wherein said inhibitor comprises an antisense polynucleotide which binds to osteonectin mRNA so as to prevent or decrease expression of human osteonectin by preventing or decreasing translation of said mRNA into human osteonectin.

Please substitute the following claim 15 for pending claim 15:

15. (twice amended) The method according to Claim 10, wherein said antisense polynucleotide is an antisense RNA complimentary to human osteonectin mRNA.

Please substitute the following claim 16 for pending claim 16:

16. (twice amended) The method according to Claim 15, wherein said inhibitor is conjugated to or administered in combination with a carrier molecule.

Please substitute the following claim 25 for pending claim 25:

25. (twice amended) A vector capable of transferring genetic material into a human cell, wherein said vector codes for an antisense polynucleotide which binds to human

osteonectin mRNA and wherein expression of said vector results in a decrease or inhibition of osteonectin activity in the cell.

Please substitute the following claim 36 for pending claim 36:

36. (once amended) The method of Claim 10, wherein the patient has cancer.